Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Vivos Therapeutics, Inc. (VVOS) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][4]. - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to assess fair value [4]. Company Performance and Investor Sentiment - The upgrade in Vivos Therapeutics' rating reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [5]. - Analysts have raised their earnings estimates for Vivos Therapeutics, with the Zacks Consensus Estimate increasing by 11.9% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Vivos Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].